Место нетиазидных сульфонамидных диуретиков в лечении артериальной гипертонии

1. Ezzati M, Lopez AD, Rodgers A et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–60.
2. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality. Lancet 2002; 360: 1903–13.
3. Cifkova at al. Atherosclerosis 2011 (2010); p. 677–1.
4. NRC. Campbell Hypertensium 2009; 53 (2): 128–34.
5. Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр). Системные гипертензии. 2010; 3: 5–26.
6. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Рос. кардиол. журн. 2006; 4: 45–50.
7. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated Meta-Analytical Approach to the Efficacy of Antihypertensive Drugs in Reducing Blood Pressure. Clin Drug Invest 2007; 27 (11): 734–52.
8. London GM. Efficacy of indapamide 1.5 mg, sustained release, in the lowering of systolic blood pressure. J Hum Hypertens 2004; 18 (Suppl. 2): S9–S14.
9. Emeriau JP, Knauf H, Pujadas JO et al. A comparison of indapamide SR 1.5 mg with both amlodipine 5mg and hydrochlorothiazide 25mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001; 19 (2): 343–50.
10. Multiple Risk Factor Intervention Trial Research group. Mortality after 10,5 years for hypertensive participants in the multiple risk factor intervention trial. Circulation 1990; 82: 1616–28.
11. Leren P, Helgeland A. Oslo hypertension study. Drugs 1986; 31: 41–5.
12. ALHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypenensive patients randomized to angiotensin-converting enzyme inhibiror or calcium channel blocker versus diuretic: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trail (ALLHAT). JAMA 2002; 288: 2981–97.
13. SHEP Cooperative Research Group. Prevention of stroke by antihypenensive drug treatment in older persons with isolated systolic hypenension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64.
14. Post-stroke antihypertensive treatment study. A preliminary result. PAT'S Collaborating Group. Chin Med J 1995; 108: 710–7.
15. Beckett NS, Peters R, FIetcher AE et al. for the HYVET Siudy Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98.
16. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41.
17. Dinicolantonio J. Hydrochlorothiazide: is it a wise choice? Expert Opin Pharmacother 2012; 13 (6).
18. Chaffman M, Heel RC, Brogden RN et al. Indapamide: a review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1984; 28 (3): 189–235.
19. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996; 77; 16 (11): 1677–84 (6): 12–16b.
20. Campbell DB, Brackman F. Cardiovascular protective properties of indapamide. Am J Cardiol 1990; 65: 11–27H.
21. Molyneaux LM, Willey KA, Yue DK. Indapamide is as effective as captopril in the control of microalbuminuria in diabetes. J Cardiovasc Pharmacol 1996; 27 (3): 424–7.
22. Carey PA, Sheridan DJ, de Cordoue A et al. Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis. Am J Cardiol 1996; 77 (6): 17–19b.
23. Damien G, Huet de Barochez B, Schiavi P. Galenic development and pharmacokinetic profile of indapamide sustained release 1.5 mg. Clin Pharmacokinet 1999; 37 (Suppl. 1): 13–9.
24. Lacourciere Y, Poirier L, Hebert D et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005; 27: 1013–21.
25. Ruilope LM, Malacco E, Khder Y et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005; 27: 578–87.
26. Brown MJ, Cruickshank JK, Dominiczak AF et al. Better blood pressure control: how to combine drugs. J Hum Hypertens 2003; 17: 81–6.
27. Chobanian AV, Bakris GL, Black HR et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood pressure: the JNC 7 report. JAMA 2003; 289: 2560–72.
28. Mancia G, De Backer G, Dominiczak A et al. Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
29. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139–85.
30. Mimran A, Weir MR. Angiotensin-receptor blockers and diuretics – advantages of combination. Blood Press 2005; 14: 6–11.
31. Akram J, Sheikh UE, Mahmood M, Donnelly R. Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study. Curr Med Res Opin 2007; 23 (12): 2929–36.
32. Кобалава Ж.Д., Котовская Ю.В., Виллевальде С.В и др. Результаты Российской научно-практической программы АРГУС-2: возможности улучшения контроля артериальной гипертонии путем рационального использования диуретиков. Лечебное дело. 2007; 3.
33. Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J 2010; 31 (23): 2837–40.
34. Sassard J, Bataillard A, McIntyre H. An overview of the pharmacology and clinical efficacy of indapamide sustained release. Fund Clin Pharmacol 2005: 19: 637–45.
35. Leonetti G. Clinical positioning of indapamide sustained release 1.5 mg in management protocols for hypertension. Drugs 2000; 59 (Suppl. 2): 27–40.
36. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335 (8693): 827–38.
37. Mancia G, Parodi A, Merlino L, Corrao G. Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens 2011, 29: 1012–8.
38. Claxton Al, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Сlin Ther 2001; 23: 1296–310.

И.И.Чукаева, Я.Г.Спирякина 

ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава РФ, Москва